Nuformix PLC - Appointment of Broker

1st December 2017, 07:30

RNS Number : 1048Y
Nuformix PLC
01 December 2017
 

Nuformix plc

("Nuformix" or "the Company")

 

Appointment of Broker

 

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce the appointment of Beaufort Securities Limited as the Company's broker.

 

Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX

and www.nuformix.com

 

 

ENDS

 

Enquiries:

Nuformix plc

Dan Gooding, Chief Executive Officer

 

+44 (0)1223 423667

 

Beaufort Securities Limited (Joint Broker)

Jon Belliss

 

+44 (0)20 7382 8300

 

Gable Communications Ltd

John Bick / Justine James

+44 (0)20 7193 7463

 

 

 

About Nuformix plc  www.nuformix.com 

 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

 

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

 

Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPFSWSWFFWSEEE ]]>

Companies mentioned in this announcement

Comments

info
Login or register to post comments